愛朋醫療(300753.SZ)半年度淨利潤升23.81%至4121.28萬元
格隆匯8月15日丨愛朋醫療(300753.SZ)發佈2019年半年度報告，實現營業收入1.69億元，同比增長28.57%；歸屬於上市公司股東的淨利潤4121.28萬元，同比增長23.81%；歸屬於上市公司股東的扣除非經常性損益後的淨利潤3783.98萬元，同比增長20.11%；基本每股收益0.51元。
報告期內，公司圍繞戰略發展方向，穩步有序地推進各項工作，積極發揮研發、生產、銷售等各方面經營優勢，兩大類主要產品營業收入皆呈現良好發展態勢。
公司疼痛管理領域用醫療器械主要產品為微電腦注藥泵、一次性注藥泵、無線鎮痛管理系統、脈搏血氧儀及傳感器等，報告期內實現營業收入1.18億元，較去年同期增長20.47%。隨着醫療改革不斷深化以及快速康復外科(EARS)理念持續普及，醫院有使用國產優質高性價比醫療器械替代進口產品的意願，醫生及病人有提升治療效果、縮短住院時間的意願，受益於此公司的疼痛管理產品銷售收入持續呈現穩定增長態勢；公司疼痛管理產品主要採用經銷模式，報告期內積極開發新的合作經銷商及終端醫院，實現期末新增經銷商66家、新增終端醫院115家。
公司鼻腔護理領域產品主要為鼻腔護理噴霧器、“小諾”海鹽水鼻腔護理噴霧、敏伴複合益生菌粉固體飲料，報告期內實現營業收入4335.48萬元，較去年同期增長36.76%。公司擁有完善的鼻腔護理器產品線以滿足不同人羣對鼻腔護理的需求，上年度新推出的高滲緩衝海水鼻腔護理噴霧器、弱酸性緩衝生理海水鼻腔護理噴霧器進一步滿足了鼻炎患者、嬰幼兒羣體的鼻腔護理需求，報告期內相應產品銷售量快速增長，展現出了良好的發展潛力。公司的鼻腔護理產品由子公司諾斯清負責銷售，諾斯清建立有立體的銷售渠道及相匹配的專業銷售團隊，通過經銷、直銷等銷售模式將產品覆蓋至醫院、院外藥房、零售藥店、互聯網銷售平台等多類型銷售終端；為進一步豐富鼻腔護理產品線，滿足不同人羣鼻腔護理需求，公司推出了“小諾”海鹽水鼻腔護理噴霧和敏伴複合益生菌粉固體飲料，報告期內公司針對系列產品作出了營銷佈局和市場推廣，收到了良好的效果。公司經過客户羣體分析，結合鼻腔護理產品特點，在報告期內加大了網絡銷售平台的營銷力度，在天貓、京東等各大網絡平台開設的直營店銷售額皆呈現出快速增長態勢，成為公司鼻腔護理產品銷售的生力軍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
